Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Facebook Stock Will Eventually Stop Falling

By Chris Lau, InvestorPlace Contributor Nov 16, 2018

FB stock is trading near yearly lows. With its solid balance sheet and growth prospects, Facebook may not stay down for too long.

This Is What You Should Expect From Nvidia Earnings This Week

By Chris Lau, InvestorPlace Contributor Nov 12, 2018

NVDA reports quarterly earnings this week, and the market already expects the worst from the company. Here's a balanced view on Nvidia stock.

Amazon Stock Is Taking a Breather, so You Should Too

By Chris Lau, InvestorPlace Contributor Nov 12, 2018

Amazon stock is tapped out for now

Continued, Reliable Improvements Make Microsoft Stock a Smart Choice

By Chris Lau, InvestorPlace Contributor Nov 9, 2018

Amazon.com blazed past Microsoft stock by market value but that ended quickly. Microsoft stock rose after its earnings report.

6 Pharmaceutical Stocks to Buy After the Midterms

By Chris Lau, InvestorPlace Contributor Nov 9, 2018

The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.

Aurora Cannabis Stocks Needs More Legal Marijuana to Grow

By Chris Lau, InvestorPlace Contributor Nov 8, 2018

Aurora Cannabis got a major tailwind when Canada became the second country to legalize marijuana, but ACB stock will need to continue growing to justify its stock price.